Although biosimilar insulin therapy is not uncommon in Asia, only one-third of patients with type 2 diabetes in Asia and 7.4% of patients with type 2 diabetes in Taiwan achieve HbA1c < 7.0% (53 mmol/mol) after 6 months of basal insulin therapy [20, 21]. The gene discussed is INS; the disease is type 2 diabetes mellitus.